Akebia Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2018 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced two posters to be presented at the upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California, from October 23 to 28, 2018.
The presentations include final results from two Phase 2 studies of vadadustat in Japanese patients with anemia associated with non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis dependent chronic kidney disease (DD-CKD), and results from a systematic literature review of the use of assessment tools to measure quality of life in patients with anemia due to CKD.
Phase 2 Clinical Trial Results in Japanese Patients:
Randomized, Placebo-Controlled Phase 2 Trials of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), to Treat Anemia of Chronic Kidney Disease (poster #TH-PO228), to be presented in the Exhibition Hall on Thursday, October 25, 2018, from 10 a.m. to 12 p.m. Pacific Time.
Quality of Life Assessment Tools:
Measuring Quality of Life in Patients with Chronic Kidney Disease Anemia – SF36 and KDQoL (poster #TH-PO265), to be presented in the Exhibition Hall on Thursday, October 25, 2018, from 10 a.m. to 12 p.m. Pacific Time.
Vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is an investigational drug that relies on the HIF pathway – the same pathway used by the body to adapt to lower oxygen availability, such as that experienced with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen levels by increasing the availability of HIF, which coordinates the interdependent processes of iron utilization and erythropoietin production to increase red blood cell production and, ultimately, improve oxygen delivery. Vadadustat has not been approved by the U.S. Food and Drug Administration or any regulatory authority.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
John Garabo, 617-844-6130
Director, Corporate Communications
Source: Akebia Therapeutics, Inc.